A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment.
Karthick Vishwanathan, Inmaculada Sanchez-Simon, Bhumsuk Keam, Nicolas Penel, Maria de Miguel-Luken, Doris Weilert, Andrew Mills, Marcelo Marotti, Alain Ravaud
The online reader was unable to display this document directly. This may occur if the repository host is temporarily unreachable, or if security restrictions (CORS) prevent embedded viewing.